MedTrace Logo

ATI-2231 in Advanced Solid Tumor Malignancies

NCT05791474 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-11-29

No results posted yet for this study

Summary

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

Conditions

  • Advanced Solid Tumor
  • Advanced Solid Tumor Malignancies

Interventions

DRUG

ATI-2231

Provided by Aclaris Therapeutics, Inc.

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Cynthia X Ma, M.D., Ph.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791474 on ClinicalTrials.gov